Domov › Akútna myeloidná leukémia › Kansas

Klinické štúdie Akútna myeloidná leukémia v štáte Kansas

20 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v štáte Kansas.

Mestá v štáte Kansas

Oficiálny text štúdie (anglicky)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Veteran Administration Eastern Kansas Healthcare, Leavenworth
a 4 ďalších

Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov

Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Indian Creek Campus, Overland Park
a 1 ďalších

Prebieha náborFáza 2

Vek 18 až 59 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Kansas Clinical Research Center, Fairway
HaysMed, Hays
University of Kansas Cancer Center, Kansas City
a 7 ďalších

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Indian Creek Campus, Overland Park
a 2 ďalších

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Westwood Cancer Center, Westwood

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Indian Creek Campus, Overland Park
a 1 ďalších

Prebieha náborFáza 2

Vek 18 až 59 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT05554406

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

US-Kansas City KS-KUMC, Fairway

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

US-Kansas City KS-KUMC, Kansas City

Prebieha náborFáza 3

Vek 18 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Indian Creek Campus, Overland Park
a 1 ďalších

Prebieha náborFáza 1

Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT05886049

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The University of Kansas Cancer Center, Kansas City

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT06001788

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

University of Kansas Cancer Center, Westwood

Prebieha náborFáza 3

Vek 18 až 75 · Všetky pohlavia · Aktualizované 17. 7. 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

University of Kansas, Westwood

Prebieha náborObservačná štúdia

Všetky vekové kategórie · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT01351545

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

University of Kansas Medical Center Research Institute, Inc., Kansas City

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 4. 2026 · NCT06146257

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

University of Kansas Cancer Center, Westwood

Prebieha náborFáza 1

Vek 18 až 65 · Všetky pohlavia · Aktualizované 25. 3. 2026 · NCT03533816

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

University of Kansas Medical Center, Westwood

Prebieha náborFáza 2

Vek 18 až 66 · Všetky pohlavia · Aktualizované 17. 3. 2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

The University of Kansas Medical Center Research Institute, Fairway

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 3. 2026 · NCT05735184

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

KU Cancer Center, Kansas City

Prebieha náborFáza 1

Vek 65 a viac · Všetky pohlavia · Aktualizované 16. 12. 2025 · NCT06552416

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

University of Kansas, Fairway

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 5. 2025 · NCT06634394

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

University of Kansas Cancer Center, Fairway

Prebieha náborFáza 2

Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 3. 2025 · NCT02781883

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

University of Kansas Cancer Center, Fairway

Prebieha náborFáza 1

Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 6. 2020 · NCT04167696

Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.